Skip to main content

Table 2 Characteristics of studies included in review

From: Systematic review of lung function and COPD with peripheral blood DNA methylation in population based studies

Study

Year

Location

Cohort

Population

Selection

COPD Definition

Qiu et al. [23]

2012

Multi-centrea

ICGN

Family-cohort of probands of COPD patients and healthy siblings/parent with >5 pack-year history of smoking

Information not available

Post-bronchodilator FEV1/FVC <0.7 and FEV1 < 70% predicted

Boston (USA)

EOCOPD

Family-cohort of probands of COPD patients with varying severity, prior to age 53, exclusion of AAT deficiency (confirmed by serum analysis), all family members had potential to be enrolled (independent of smoking status)

Cases identified from Lung Transplant/Reduction Surgical Programs at Brigham and Women’s Hospital and Massachusetts General Hospital. Pulmonary Clinics at these hospitals and associated hospitals served as additional source of participants [32]

Post-bronchodilator FEV1/FVC  < 0.7 and FEV1 < 70% predicted

Bell et al. [22]

2012

UK

Twins UK

Healthy unselected volunteers who are a twin (MZ, DZ and singleton) representing the general population

Participants recruited from media campaigns, initially only middle-aged women were included in the registry but from 1995 onwards, men and women >18 years of age were also recruited [28]

Analysed lung function only (no COPD diagnosis) –

FEV1 and FVC

Lepeule et al. [25]

2012

USA

Normative Ageing

Healthy male participants at enrolment, containing smokers and ex-smokers (Veterans Administration 1963 closed-cohort)

Enrolled after an initial health screening determined that they were free of known chronic medical conditions

Analysed lung function –

FEV1, FVC, MMEF (did not specify pre-/post-bronchodilator)

Lange et al. [26]

2012

Boston (USA)

Normative Ageing

Healthy male participants at enrolment, containing smokers and ex-smokers (Veterans Administration 1963 closed-cohort)

Enrolled after an initial health screening determined that they were free of known chronic medical conditions

GOLD stage II or higher (pre-bronchodilator FEV1/FVC < 0.7 and FEV1 < 80% predicted)

Marioni et al. [21]

2015

Scotland (UK)

Lothian Birth

Childhood inception cohort of ‘healthyb’ participants with varying lung function, containing smokers, ex-smokers and never smokers

Individuals born in 1936 in the Lothian area were identified using the Community Health Index (registered at a general practitioner) or through media advertisements. The majority of the cohort were participants in the Scottish Mental Survey 1947 [27]

Analysed lung function only (no COPD diagnosis)-

FEV1

Wielscher et al. [24]

2015

Austria

N/A

COPD patients, GOLD 0 COPD patients and healthy controls

Selection of patient from Medical University of Vienna, 2008-2012

Post-bronchodilator FEV1/FVC <0.7

  1. Abbreviations: ICGN International COPD Genetics Network
  2. aMulti-centre: Cambridge, Copenhagen, Denver, Harvard, Holland, Italy, Liverpool, Nebraska, Spain, Vancouver EOCOPD: Early-onset COPD (Boston), AAT: Alpha-1-Antitrypsin, UK: United Kingdom, MZ: Monozygotic twin, DZ: Dizygotic twin, USA: United States of America, GOLD: Global Initiative for Chronic Obstructive Lung Disease
  3. bHealthy: participants free from chronic disease at enrolment, GOLD stage 0: FEV1/FVC ratio > 0.7 but with respiratory symptoms